Approval · Notice of Compliance 19587 · 2017
EMEND IV: Notice of Compliance 19587
Issued July 26, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19587
- Date
- July 26, 2017
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Include males in the indication for the prevention of nausea and vomiting due to treatment with moderately emtogenic chemotherapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EMEND IV | Not yet assigned | — |
Medicinal ingredients
- FOSAPREPITANT DIMEGLUMINE 150 MG per VIAL